- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06261957
Um estudo para avaliar e comparar a segurança e tolerabilidade do tratamento de 3 meses com salbutamol administrado via MDI contendo propelente HFA-152a ou HFA-134a em participantes com 12 anos de idade ou mais com asma
Um estudo randomizado, duplo-cego, de grupo paralelo e multicêntrico para avaliar a segurança a longo prazo do medicamento de resgate Salbutamol quando administrado por meio de inaladores de dose medida contendo o propelente HFA-152a ou referência HFA-134a
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Buenos Aires, Argentina, C1425BEN
- GSK Investigational Site
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Buenos Aires, Argentina, C1425AZE
- GSK Investigational Site
-
La Plata, Argentina, 1900
- GSK Investigational Site
-
Mendoza, Argentina, M5500CCG
- GSK Investigational Site
-
-
-
-
New South Wales
-
Botany, New South Wales, Austrália, 2019
- GSK Investigational Site
-
Coffs Harbour, New South Wales, Austrália, 2450
- GSK Investigational Site
-
Kanwal, New South Wales, Austrália, 2259
- GSK Investigational Site
-
-
Western Australia
-
Spearwood, Western Australia, Austrália, 6163
- GSK Investigational Site
-
-
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S 2J5
- GSK Investigational Site
-
Brampton, Ontario, Canadá, L6T 0G1
- GSK Investigational Site
-
Ottawa, Ontario, Canadá, K1H 1E4
- GSK Investigational Site
-
Toronto, Ontario, Canadá, M9V 4B4
- GSK Investigational Site
-
Windsor, Ontario, Canadá, N8X 2G1
- GSK Investigational Site
-
-
Quebec
-
Québec, Quebec, Canadá, G1V 4W2
- GSK Investigational Site
-
Québec, Quebec, Canadá, G1W 4R4
- GSK Investigational Site
-
-
-
-
-
Barcelona, Espanha, 08017
- GSK Investigational Site
-
Barcelona, Espanha, 08540
- GSK Investigational Site
-
Benalmádena, Espanha, 29631
- GSK Investigational Site
-
Madrid, Espanha, 28041
- GSK Investigational Site
-
Madrid, Espanha, 28040
- GSK Investigational Site
-
Madrid, Espanha, 28031
- GSK Investigational Site
-
Marbella, Espanha, 29603
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Espanha, 28223
- GSK Investigational Site
-
-
-
-
California
-
North Hollywood, California, Estados Unidos, 91606-3287
- GSK Investigational Site
-
San Mateo, California, Estados Unidos, 94403
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- GSK Investigational Site
-
Clearwater, Florida, Estados Unidos, 33756
- GSK Investigational Site
-
DeLand, Florida, Estados Unidos, 32720
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33173
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33144
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33155
- GSK Investigational Site
-
Naples, Florida, Estados Unidos, 34102
- GSK Investigational Site
-
Plantation, Florida, Estados Unidos, 33317
- GSK Investigational Site
-
Winter Park, Florida, Estados Unidos, 32789-3385
- GSK Investigational Site
-
-
Georgia
-
Rincon, Georgia, Estados Unidos, 31326-5131
- GSK Investigational Site
-
Stonecrest, Georgia, Estados Unidos, 30038
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40217
- GSK Investigational Site
-
Owensboro, Kentucky, Estados Unidos, 42301
- GSK Investigational Site
-
-
Massachusetts
-
Fall River, Massachusetts, Estados Unidos, 02723-1511
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55402-2508
- GSK Investigational Site
-
Minneota, Minnesota, Estados Unidos, 56001
- GSK Investigational Site
-
-
Mississippi
-
Olive Branch, Mississippi, Estados Unidos, 38654
- GSK Investigational Site
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65203
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Estados Unidos, 89052-5015
- GSK Investigational Site
-
-
New Jersey
-
Jersey City, New Jersey, Estados Unidos, 07306
- GSK Investigational Site
-
Riverdale, New Jersey, Estados Unidos, 07457
- GSK Investigational Site
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11220
- GSK Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28803
- GSK Investigational Site
-
Winston-Salem, North Carolina, Estados Unidos, 27104
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45231
- GSK Investigational Site
-
Dublin, Ohio, Estados Unidos, 43016
- GSK Investigational Site
-
-
Oregon
-
Medford, Oregon, Estados Unidos, 97504
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- GSK Investigational Site
-
Pottstown, Pennsylvania, Estados Unidos, 19464-3241
- GSK Investigational Site
-
-
South Carolina
-
Rock Hill, South Carolina, Estados Unidos, 29732
- GSK Investigational Site
-
Spartanburg, South Carolina, Estados Unidos, 29303
- GSK Investigational Site
-
Spartanburg, South Carolina, Estados Unidos, 29303-4225
- GSK Investigational Site
-
Union, South Carolina, Estados Unidos, 29379-7409
- GSK Investigational Site
-
-
Texas
-
Sugar Land, Texas, Estados Unidos, 77479
- GSK Investigational Site
-
Tomball, Texas, Estados Unidos, 77375-3332
- GSK Investigational Site
-
-
-
-
-
Iloilo City, Filipinas, 5000
- GSK Investigational Site
-
-
-
-
-
Amiens, França, 80054
- GSK Investigational Site
-
Argenteuil, França, 95100
- GSK Investigational Site
-
Créteil, França, 94010
- GSK Investigational Site
-
Poitiers, França, 86021
- GSK Investigational Site
-
Pontoise, França, 95303
- GSK Investigational Site
-
Strasbourg, França, 67091
- GSK Investigational Site
-
-
-
-
-
Athens, Grécia, 15669
- GSK Investigational Site
-
Larissa, Grécia, 41110
- GSK Investigational Site
-
Thessaloniki, Grécia, 57010
- GSK Investigational Site
-
-
-
-
-
Cagliari, Itália, 09042
- GSK Investigational Site
-
Florence, Itália, 50134
- GSK Investigational Site
-
Foggia, Itália, 71100
- GSK Investigational Site
-
Milan, Itália, 20162
- GSK Investigational Site
-
Naples, Itália, 80131
- GSK Investigational Site
-
Padova, Itália, 35128
- GSK Investigational Site
-
Torino, Itália, 10128
- GSK Investigational Site
-
Tradate VA, Itália, 21100
- GSK Investigational Site
-
Verona, Itália, 37134
- GSK Investigational Site
-
-
RM
-
Roma, RM, Itália, 00161
- GSK Investigational Site
-
-
-
-
-
Panama City, Panamá
- GSK Investigational Site
-
Panama City, Panamá, 7099
- GSK Investigational Site
-
Panama City, Panamá, 7002
- GSK Investigational Site
-
-
-
-
-
Bialystok, Polônia, 15-010
- GSK Investigational Site
-
Bielsko-Biala, Polônia, 43-300
- GSK Investigational Site
-
Chorzów, Polônia, 41-500
- GSK Investigational Site
-
Elblag, Polônia, 82-300
- GSK Investigational Site
-
Katowice, Polônia, 40-600
- GSK Investigational Site
-
Ostrowiec Świętokrzyski, Polônia, 27-400
- GSK Investigational Site
-
Płock, Polônia, 09-407
- GSK Investigational Site
-
Tarnów, Polônia, 33-100
- GSK Investigational Site
-
-
-
-
-
Bebington, Reino Unido, CH63 9JP
- GSK Investigational Site
-
Cambridgeshire, Reino Unido, CB7 5JD
- GSK Investigational Site
-
Corby, Reino Unido, NN17 2UR
- GSK Investigational Site
-
Greater Manchester, Reino Unido, OL6 6HD
- GSK Investigational Site
-
Guisborough, Reino Unido, TS14 7DJ
- GSK Investigational Site
-
Hounslow, Reino Unido, TW3 3EL
- GSK Investigational Site
-
Rhyl, Reino Unido, LL18 4HZ
- GSK Investigational Site
-
Uttoxeter, Reino Unido, ST14 5JX
- GSK Investigational Site
-
-
-
-
-
Pathum Thani, Tailândia, 12120
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.
-
Asthma for ≥ 6 months, defined as:
-
Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]
-
Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
- Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
- Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
- Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
- Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
-
-
Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)
-
Asthma Control Status
-
Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening
-
Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
- Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
- An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
-
-
Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.
-
Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
-
With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
-
Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
- SABA should be withheld for ≥6 hours
- Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
-
Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
- SABA should be withheld for ≥6 hours
- LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.
-
Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
Exclusion Criteria:
- A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
- Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
- Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
- Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Salbutamol HFA-152a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 μg (ex-valve) at 30-second intervals per actuation |
|
Comparador Ativo: Salbutamol HFA-134a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 microgram (μg) (ex-valve) at 30-second intervals per actuation |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) During Run-in Period
Prazo: From Week -1 up to randomization (Day 1) during Run-in period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Adverse Events (AEs) During Treatment Period
Prazo: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
Prazo: From Week -1 up to randomization (Day 1) during Run-in period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
Prazo: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
|
Absolute Values of Minimum Serum Potassium
Prazo: Up to Week 13 (Follow up)
|
Blood samples were collected to analyze minimum serum potassium. |
Up to Week 13 (Follow up)
|
|
Absolute Values of Serum Potassium at Each Assessed Visit
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Erythrocytes
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Erythrocytes
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCV
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCH
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hematocrit
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hematocrit
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Specific Gravity
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Specific Gravity
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
Prazo: Up to Week 13 (Follow up)
|
Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result. |
Up to Week 13 (Follow up)
|
|
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Vital Signs: Pulse Rate
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Pulse Rate
Prazo: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
Prazo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline for 12 Lead ECGs in QTcF
Prazo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Heart Rate
Prazo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Heart Rate
Prazo: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
Prazo: Baseline (Day 1, pre-dose) and Week 12
|
The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
|
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Prazo: Baseline (Day 1, pre-dose) and Week 12
|
Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: GSK Clinical Trials, GlaxoSmithKline
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 220735
- 2023-509001-76-00 (Outro identificador: EU CT Number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Prazo de Compartilhamento de IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Critérios de acesso de compartilhamento IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .